EnglishРусский中文EspañolDeutsch
Independent world news

Pancreatic cancer pill shrinks tumours in 61-patient trial

An experimental daily pill, daraxonrasib, shrank or eliminated tumours in about 61% of patients with advanced pancreatic cancer in an early-stage trial, and Cancer Research UK called the result the biggest advance in decades.

Pancreatic cancer pill shrinks tumours in 61-patient trial
Photo: Scientific Animations Inc. / Wikimedia Commons, CC BY-SA 4.0

Results from a phase 1/2 study of 61 patients with advanced pancreatic cancer were presented at a medical conference in Barcelona, according to the Guardian and other outlets. Tumours shrank or disappeared in 60.7% of participants, and in nearly all of them tumour growth was halted.

The cancer became undetectable on scans in roughly one in 12 patients. The median time before the disease progressed or the patient died was 12.8 months, the reports said.

Michelle Mitchell, chief executive of Cancer Research UK, described the findings as the biggest leap forward in decades for pancreatic cancer patients. She added that further trials are needed before the drug could be used in the NHS.

Daraxonrasib is an oral inhibitor of RAS proteins, which drive growth in most pancreatic tumours. It is being developed by the US company Revolution Medicines.

Researchers stressed the limits of the data. The study was small, had no comparison group, and does not show that the treatment cures the disease. Patients in such trials are usually well enough to receive therapy, so results may not apply to everyone with advanced cancer. Regulatory status reported by different outlets conflicts, and approval could not be confirmed from a primary source.

Pancreatic cancer is among the deadliest common cancers, often found late. Company filings say a larger phase 3 trial, RASolute 302, reported positive results in previously treated patients earlier this year, and another, RASolute 303, is testing the drug as a first treatment.

daraxonrasibpancreatic cancer pillpancreatic cancer treatmentRevolution MedicinesCancer Research UKRAS inhibitor
More in Science